USE OF ALPHA-(8-QUINOLINYLOXY) MONO-SUBSTITUTED PHTHALOCYANINE ZINC FOR TREATMENT OF PSORIASIS

Abstract

The present invention relates to a use of alpha-(8-quinolinyloxy) mono-substituted phthalocyanine zinc for the treatment of psoriasis. The use is suitable for various type of psoriasis by utilizing photodynamic therapy. The photosensitizer is used to treat psoriasis by utilizing laser wave length of 670 nm, with high light sensitivity, fast photobleaching, short time needed in protection from light, and avoiding potential toxic and side-effect of photochemistry therapy by using ultraviolet irradiation. The preparation used in the use of -(8-quinolinyloxy) mono-substituted phthalocyanine zinc for the treatment of psoriasis includes solution, cream, nanomicelle, microsphere etc, and mode of administration can be systemic or topical administration. The practicability of treating psoriasis by photodynamic therapy has been validated on cell and animal model. The use achieves perfect effect.

Claims

1-4. (canceled)

5. A method of treating psoriasis of a human patient, the method comprising: using alpha-(8-quinolinyloxy) mono-substituted phthalocyanine zinc as a photosensitizer, the alpha-(8-quinolinyloxy) mono-substituted phthalocyanine zinc having the following structural formula: ##STR00001##

6. The method of claim 5, further comprising treating psoriasis of the following types: psoriasis vulgaris, pustular psoriasis, erythrodermic psoriasis, or arthritic psoriasis.

7. The method of claim 5, wherein the method of treating comprises a photodynamic therapy using a semiconductor laser with a wavelength of 670 nm as a light source.

8. The method of claim 5, further comprising providing the alpha-(8-quinolinyloxy) mono-substituted phthalocyanine zinc in a formulation comprising a solution, a cream, a nanomicelle, a microsphere, or a patch.

9. The method of claim 6, wherein the psoriasis is classified into blood heat type, blood dryness type or blood stasis type.

10. The method of claim 5, wherein the psoriasis occurs in any body part of the human patient.

11. The method of claim 5, wherein the method of treatment comprises a photodynamic therapy using a semiconductor laser.

12. The method of claim 5, wherein the method of treatment comprises a photodynamic therapy using a light source.

13. The method of claim 5, further comprising a mode of administration of the alpha-(8-quinolinyloxy) mono-substituted phthalocyanine zinc as a systemic or topical administration.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0020] FIG. 1: Mouse vaginal epithelial basal cells and mitotic cells.

[0021] FIG. 2: Effect of -(8-quinolinyloxy) mono-substituted phthalocyanine zinc on the diethylstilbestrol-induced excessive proliferation of mouse vaginal epithelial cells. HE staining. A, blank control group (200); B, model control group (200); C, irradiation without administration group (200); D, PDT group 1 (200); E, PDT group 2 (200) and F, PDT group 3 (200).

[0022] FIG. 3: Propranolol-induced psoriasis-like lesions on guinea pig ears. A, normal guinea pig ear. B, model guinea pig ear; changes such as scales, dilatation of blood vessels, thickening of skin can be observed. C, acanthosis (HE staining, 40). D, hyperkeratosis accompanied with parakeratosis (HE staining, 200).

[0023] FIG. 4: Therapeutic effect of -(8-quinolinyloxy) mono-substituted phthalocyanine zinc on propranolol-induced psoriasis-like lesions in guinea pigs. HE staining, 40.